AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03044574 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: GCS
Description: Thigh-length graduated compression stockings with pressure of 18-21 mm. Hg at the ankle used all the time until discharge plus one month after discharge
Study NCT03044574 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GCS
Description: Thigh-length graduated compression stockings with pressure of 18-21 mm. Hg at the ankle used all the time until discharge plus one month after discharge
Study NCT03044574 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LMWH
Description: LMWH enoxaparin (Clexane) 40 mg once a day subcutaneously started on 1st or 2-5th postoperative day according to the bleeding risk and used until discharge.
Study NCT03044574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LMWH
Description: LMWH enoxaparin (Clexane) 40 mg once a day subcutaneously started on 1st or 2-5th postoperative day according to the bleeding risk and used until discharge.
Study NCT00890045 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HeRO Vascular Access Device
Description: HeRO Vascular Access Device
Study NCT00890045 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional ePTFE hemodialysis graft
Description: Conventional ePTFE hemodialysis graft
Study NCT02166177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Autologous regulatory T cell product
Description: Autologous regulatory T cell therapy infused intravenously (2 dose groups: low dose and high dose). The patients also receive rabbit Antithymocyte Globulin (rATG), tacrolimus, and sirolimus.
Study NCT02390791 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: enhanced myADHDportal.com
Description: Version of the myADHDportal.com web software enhanced with family-management support to enable parents to be active partners in optimizing and maintaining medication continuity for their child
Study NCT02390791 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: treatment as usual standard portal
Description: Standard version of myADHDportal.com web software
Study NCT03971877 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Rapid Polymyxin NP test
Description: From rectal swabs of patients admitted in ICU and oncohaematology ward, investigators will use first a new culture medium (SuperPolymyxin) for screening the colistin resistant Gram negative and then a new rapid test (Rapid Polymyxin NP test) to confirm this resistance. These tests will be compared to the reference test of MIC (Minimal Inhibitory Concentration) determined by the broth micro-dilution (BMD) method.
Study NCT02986776 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Outpatient Care
Description: 21 days of outpatient substance misuse treatment
Study NCT02827968 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KN035
Description: KN035 is a monoclonal antibody drug which is formulated for subcutaneous injection in a single-use vial (brown neutral borosilicate) containing a total of 300 mg antibody in 1.5 ml of solution.
Study NCT01909102 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACT-based intervention
Study NCT01909102 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: usual care
Study NCT01746017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2922470
Description: Administered orally as capsules
Study NCT00501345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: 325 mg by mouth on Day 1 only, followed by 160 mg by mouth daily
Study NCT02321566 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Epidural Motor Cortex Stimulation
Study NCT01159262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Study NCT00193804 — intervention group
Intervention type: RADIATION
Intervention: IMRT
Description: IMRT in cervical cancers
Study NCT04657848 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: proximal gastrectomy combined with Cheng's Giraffe reconstruction
Description: proximal gastrectomy combined with gastric tube interposition esophagogastrostomy with reconstruction of His angle and fundus (Cheng's Giraffe reconstruction)
Study NCT00867750 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radioembolisation (SIR-Spheres® microspheres)
Description: Yttrium-90 SIR-Spheres microspheres
Study NCT00867750 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Transarterial Chemoembolisation
Description: TACE with embolising agent Embospheres (150-300 μm or 300-500 μm diameter) with 50 mg of chemotherapeutic agent epirubicin admixed with 5 ml lipiodol.
Study NCT03796403 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Diclofenac
Description: Twenty mL of bupivacaine was infiltrated into surgical-site peritoneum , divided in 10 sites before closure, and diclofenac 75 mg (3 mL) was intramuscularly injected immediately after complete the procedure and the operative field was covered with sterile adhesive wound dressing.
Study NCT03796403 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diclofenac
Description: Twenty mL of bupivacaine was infiltrated into surgical-site peritoneum , divided in 10 sites before closure, and diclofenac 75 mg (3 mL) was intramuscularly injected immediately after complete the procedure and the operative field was covered with sterile adhesive wound dressing.
Study NCT02278783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: regorafenib
Description: Patients will be treated with Regorafenib 160 mg (4 x 40 mg tablets) daily for 21 days of a 28 day cycle (three weeks on drug, one week off) until disease progression or adverse effects prohibit further treatment
Study NCT05462184 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive-Behavioral Therapy (CBT)
Study NCT05462184 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Study NCT01499290 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAZ-AVI
Description: Ceftazidime 2000 mg and 500 mg of avibactam
Study NCT01499290 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole
Description: 500 mg of Metronidazole
Study NCT01499290 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meropenem
Description: 1 gram of Meropenem
Study NCT03365388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Hyaluronate
Description: Hyaluronic acid is a component of synovial fluid. N- is glucuronic acid and N-acetylglucosamine repeating disaccharide unit form
Study NCT03365388 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aerzhi
Description: Sodium Hyaluronate Injection can cover and protect joint tissue, improve lubrication function, and penetrate degenerative cartilage
Study NCT00550498 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Stem Cell Transplantation
Description: Autologous bone marrow aspiration (20 ml) from iliac crest. Separation of mononuclear cells using ficoll hypaque and culture in 10% fetal bovine serum and Dulbecco modified eagles medium. After confluent stage, detachment of cells with trypsin/EDTA, and subculture. Repeated passages until obtainment of required cell number. Confluent cells of last passage are washed with tyrode solution and incubate with M199 for 60 minutes. Cells are separated using trypsin/EDTA and washed 3 times with M199 and 1% HSA. Precipitate will be diluted with heparinized M199 to make solution with 6×106 cells /ml. Sample will be tested for viability and detection of CD45, CD34, CD90, CD44, CD13, CD105, and CD166 before injection. The number of cells for injection will be between 3-5 million cells, in a maximum volume of 0.3 ml. Cells will be injected in vitreal at 3.5 millimeter of limbus with a 26 gauge insulin needle.
Study NCT04106414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 480 mg every 4 weeks.
Study NCT04106414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS- 986205
Description: BMS-986205 100 mg every 4 weeks.
Study NCT02972476 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide & formoterol fumarate and Aclidinium bromide
Study NCT02972476 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone 500 & salmeterol and Aclidinium bromide
Study NCT02972476 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone 250 & salmeterol and Aclidinium bromide
Study NCT02972476 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aclidinium bromide & formoterol fumarate
Study NCT04240678 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic HBV Alert
Description: Electronic HBV Alert deployed in electronic medical charts of at risk patients
Study NCT04223492 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Liquid biopsy
Description: A blood sample containing circulating tumor DNA and circulating tumor cells.
Study NCT04223492 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Multi-parametric MRI
Description: Multi-parametric MRI combines different imaging protocols in one session to measure more functional items than perfusion alone, addressing different aspects of tumor biology.
Study NCT03625908 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: OCT-guided PCI
Description: Patients will receive PCI under OCT-guidance. Predefined criteria for optimization of PCI under OCT-guidance will be recommended to achieve as far as possible.
Study NCT03625908 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Angiography-guided PCI
Description: Stent optimization using high-pressure non-compliance balloon will be highly recommend. Balloon size would not be less than the stent diameter.
Study NCT03681223 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vertessa® Lite Y mesh
Description: Via randomization, 50 surgical subjects will receive Vertessa® lite Y mesh for the treatment of vaginal vault prolapse. The patient will be blinded as to which mesh they receive.
Study NCT03681223 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Restorelle® Y mesh
Description: Via randomization, 50 surgical subjects will receive Restorelle® Y mesh for the treatment of vaginal vault prolapse.The patient will be blinded as to which mesh they receive.
Study NCT03681223 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic sacrocolpopexy
Description: The subject's surgeon will decide if their patient should have laparoscopic sacrocolpopexy upon their clinical evaluation
Study NCT03681223 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic sacrocolpopexy
Description: The subject's surgeon will decide if their patient should have laparoscopic sacrocolpopexy upon their clinical evaluation
Study NCT01181622 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: denufosol tetrasodium Inhalation Solution
Description: 60 mg by oral inhalation three times daily
Study NCT01181622 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% w/v sodium chloride solution
Description: 0.9% w/v sodium chloride solution by oral inhalation three times daily
Study NCT01199718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CX-4945
Description: CX-4945 capsules, administered orally,as escalating doses. Dose schedule: four times daily for 21 consecutive days every 28 days.
Study NCT00863083 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Multifamily weight management intervention
Description: 8 week multifamily group weight management intervention incorporating behavioral health, nutrition, and activity disciplines.
Study NCT03681223 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Robotic assisted laparoscopic sacrocolpopexy
Description: The subject's surgeon will decide if their patient should have robotic assisted laparoscopic sacrocolpopexy upon their clinical evaluation
Study NCT03681223 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robotic assisted laparoscopic sacrocolpopexy
Description: The subject's surgeon will decide if their patient should have robotic assisted laparoscopic sacrocolpopexy upon their clinical evaluation
Study NCT01503671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Atorvastatin 40 mg/day
Study NCT01411553 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Disposable ECG-LW
Description: Disposable ECG leadwires used in ICU and telemetry monitoring; 5 lead sets for ICU and 6-lead sets for telemetry
Study NCT01922401 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: inverse ratio ventilation
Description: change the I: E ratio 1:2-1:1-2:1
Study NCT00721253 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ReSTOR
Description: Implantation of the ReSTOR Aspheric +4 (SN6AD3) multifocal intraocular lens (IOL)
Study NCT00721253 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tecnis
Description: Implantation with the Tecnis multifocal (ZM900) intraocular lens (IOL)
Study NCT00721253 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acri.LISA
Description: Implantation with the Acri.LISA 366D multifocal intraocular lens (IOL)
Study NCT04309799 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Tear Restore Mask
Description: The Tear Restore Mask will be used for 10 minutes
Study NCT01114230 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGS-16M8F
Description: IV
Study NCT01238588 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Sevelamer Carbonate (Renvela)
Description: Patients' will be given doses of Renvela equivalent to their prior dose of calcium based phosphate binders and the dose will be titrated as necessary to achieve phosphate levels recommended by KDOQI guidelines.
Study NCT03289520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Study NCT03289520 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03367247 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BOLSTER
Description: BOLSTER provides patients and caregivers with education and skills training, symptom management, and support across care settings over a four-week period.
Study NCT03367247 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Enhanced Discharge Planning (EDP)
Description: EDP provides patients and caregivers a single session of education and skills training, symptom management, and support.
Study NCT02635646 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Family and interdisciplinary approach
Description: Family and interdisciplinary approach that includes:~1. nutritional counseling,~2. physical activity counseling,~3. psychological counseling,~4. metformin 850mg twice at day for 12 months All this with the purpose to improve insulin resistance and insulin secretion in patients with prediabetes. Patients must attend a monthly session together with his family where they will receive the nutritional, physical activity and psychological counseling.
Study NCT02635646 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: individual approach
Description: individual approach that includes:~1. nutritional and physical activity counseling in individual appointments,~2. metformin 850mg twice at day for 12 months, All this with the purpose to improve insulin resistance and insulin secretion. The patients must attend a monthly follow-up individually.
Study NCT03011892 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib 0.15% Cream QD
Description: Ruxolitinib 0.15% cream QD
Study NCT03011892 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib 0.5% Cream QD
Description: Ruxolitinib 0.5% cream QD
Study NCT01746329 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tea
Description: Oral intake of tea containing 75 grams of glucose
Study NCT01746329 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Beet root
Description: Oral intake of beetroot juice containing 75 grams of glucose
Study NCT01746329 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral intake of 75 grams of glucose in water
Study NCT01903161 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: delayed remote ischemic preconditioning
Description: In the delayed RIPC group, RIPC is performed 24-48 hr before surgery by 5 minutes limb ischemia and reperfusion with pneumatic cuff up to 200 mmHg repeated by four times.
Study NCT01903161 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: control
Description: In the control group, all the procedures were the same with delayed RIPC group, except for the fact that the three-way stopcock between the pneumatic cuff and the cuff inflator was opened and therefore the cuff pressure did not increase.
Study NCT01597245 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 80 mg ixekizumab Dosing Regimen
Description: Administered SC
Study NCT01597245 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 50 mg etanercept
Description: Administered SC
Study NCT01597245 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study NCT03749512 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Complete blood count
Description: During routine preoperative blood test complete blood count is taken.
Study NCT03749512 — intervention group
Intervention type: OTHER
Intervention: Histopathological examination
Description: Routine postoperative histopathological examination of lung tumor.
Study NCT04459585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran Etexilate Mesylate
Description: Single oral 150 mg capsule dose
Study NCT01909102 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: usual care
Study NCT04459585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quizartinib
Description: Single oral 60 mg dose of quizartinib administered as two 30 mg tablets (26.5 mg free base per tablet)
Study NCT01229618 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperpolarized Pyruvate (13C) injection
Description: single hyperpolarized pyruvate IV (intravenous) injection followed by MR imaging scans (MRI and MRSI)
Study NCT03053674 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Follow-up questionnaire
Description: Follow-up questionnaire to determine whether participants have receive post-partum vaccination
Study NCT03053674 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Follow-up questionnaire
Description: Follow-up questionnaire to determine whether participants have receive post-partum vaccination
Study NCT01868074 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insole
Description: Custom-molded arch-supporting insole
Study NCT01794715 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound examination by nurses
Description: Ultrasound examination performed by nurses. Focused examination of the pleural space and inferior vena cava.
Study NCT01794715 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound examination by nurses
Description: Ultrasound examination performed by nurses. Focused examination of the pleural space and inferior vena cava.
Study NCT00612287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: buprenorphine
Description: Sublingual buprenorphine; product name Suboxone® (buprenorphine/naloxone). Dosing is informed by a clinical guideline which permits flexibility dependent up physician's clinical judgment. During the induction period (Day 1, at the physician's office) the first dose is 2 mg and can be brought up to 20 mg depending on patient's response. On Day 2 going forward dose can range from 2 mg q8h to 12 mg q8h. Rescue doses with buprenorphine are also permitted.
Study NCT00704691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide 25 mg as a daily oral dose days 1-21 followed by a 7 day rest period (28 day cycle) for 1-6 cycles
Study NCT01650350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: 4.1 Low Dose Naltrexone (LDN) LDN, 5 mg/day, at approximately 9pm, on an empty stomach, until disease progression, unacceptable toxicity, need for initiation of narcotic analgesia, or removal from protocol treatment according to section 12.0. (1 cycle = 28 days).~LDN, 5mg/ml, will be prepared by the Lifespan hospital pharmacy for patient use for this study.
Study NCT03858777 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: cell free DNA
Description: All groups will have blood draws and cfDNA measured
Study NCT03858777 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: cell free DNA
Description: All groups will have blood draws and cfDNA measured
Study NCT03858777 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: cell free DNA
Description: All groups will have blood draws and cfDNA measured
Study NCT02241434 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stem Cell
Description: Intrathecal autologous bone marrow mononuclear cell transplantation
Study NCT01940341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAF
Description: 25 mg tablet administered orally once daily
Study NCT01940341 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TDF
Description: 300 mg tablet administered orally once daily
Study NCT01940341 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TAF Placebo
Description: Tablet administered orally once daily